Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IMNN

Imunon Inc

Sep 16 • 04:00PM ET

1.08

Dollar change +0.04
Percentage change 3.85	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.92	Insider Own	4.93%	Shs Outstand	14.40M	Perf Week	0.93%
Market Cap	15.55M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	7.58%	Shs Float	13.69M	Perf Month	8.00%
Income	-18.08M	PEG	-	EPS next Q	-0.36	Inst Own	11.06%	Short Float	2.80%	Perf Quarter	-3.57%
Sales	0.00M	P/S	-	EPS this Y	21.99%	Inst Trans	-24.71%	Short Ratio	0.13	Perf Half Y	25.58%
Book/sh	0.40	P/B	2.71	EPS next Y	31.95%	ROA	-94.15%	Short Interest	0.38M	Perf Year	-5.26%
Cash/sh	0.37	P/C	2.93	EPS next 5Y	-	ROE	-143.19%	52W Range	0.48 - 3.65	Perf YTD	58.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.62%	ROI	-391.89%	52W High	-70.41%	Beta	2.14
Dividend TTM	-	Quick Ratio	1.51	Sales past 5Y	-20.00%	Gross Margin	100.00%	52W Low	125.00%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.51	EPS Y/Y TTM	51.02%	Oper. Margin	0.00%	RSI (14)	46.66	Volatility	6.03% 8.87%
Employees	33	Debt/Eq	0.37	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	9.75
Option/Short	No / Yes	LT Debt/Eq	0.23	EPS Q/Q	16.29%	Payout	-	Rel Volume	0.05	Prev Close	1.04
Sales Surprise	-	EPS Surprise	5.56%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	3.01M	Price	1.08
SMA20	-5.39%	SMA50	-13.37%	SMA200	0.49%	Trades		Volume	157,198	Change	3.85%

Sep-09-24 04:06PM	UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
08:30AM	IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
Aug-28-24 08:30AM	IMUNON to Host R&D Day on September 18th (GlobeNewswire)
Aug-14-24 08:00AM	IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -11.44%
Aug-07-24 05:04PM	IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024 (GlobeNewswire) -7.76%
11:54AM	Loading…
Jul-31-24 11:54AM	Imunons shares soar after IL-12 therapy success in Phase II trial (Pharmaceutical Technology) -59.34%
08:00AM	IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Jul-30-24 08:00AM	IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 (GlobeNewswire) +178.99%
Jul-29-24 04:05PM	IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow (GlobeNewswire)
Jun-24-24 08:30AM	IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Jun-05-24 08:30AM	First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial (GlobeNewswire)
May-15-24 08:30AM	Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 06:08AM	Q1 2024 Imunon Inc Earnings Call (Thomson Reuters StreetEvents) -9.12%
03:02AM	Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-13-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q1 2024 (InvestorPlace) +7.25%
09:00AM	Loading…
09:00AM	IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study (GlobeNewswire)
08:00AM	IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 08:00AM	IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO (GlobeNewswire) +17.19%
May-06-24 11:00AM	IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 (GlobeNewswire)
Apr-18-24 08:30AM	IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 (GlobeNewswire)
Apr-11-24 08:00AM	IMUNON Reports Compliance with Nasdaq Listing Requirements (GlobeNewswire) +6.21%
Apr-01-24 07:08PM	Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript (Insider Monkey) +17.68% -9.33%
Mar-28-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q4 2023 (InvestorPlace) +17.14%
08:00AM	IMUNON Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 08:30AM	IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses (GlobeNewswire)
Mar-21-24 05:00PM	IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 (GlobeNewswire) +6.42% +6.01%
Mar-13-24 08:00AM	IMUNON Files IND Application to Begin Human Testing of IMNN-101 (GlobeNewswire) -6.34%
Mar-12-24 05:00PM	IMUNON Announces Leadership Change (GlobeNewswire) -5.98%
Feb-29-24 08:30AM	Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 (GlobeNewswire) +16.33%
Feb-27-24 08:30AM	Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer (GlobeNewswire) +16.37%
08:00AM	Loading…
Feb-22-24 08:00AM	IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine (GlobeNewswire) +5.23%
Dec-11-23 08:30AM	IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 06:45PM	Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 09:00AM	IMUNON's VP of R&D to Present at the Vaccines Summit-2023 (GlobeNewswire)
08:00AM	IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-23 08:30AM	IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023 (GlobeNewswire)
Oct-23-23 08:30AM	IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress (GlobeNewswire) +7.53%
Oct-19-23 08:30AM	IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations (GlobeNewswire)
Oct-18-23 08:30AM	IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer (GlobeNewswire)
Oct-06-23 08:30AM	IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board (GlobeNewswire)
Sep-28-23 08:30AM	IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer (GlobeNewswire) -6.86%
Sep-26-23 08:30AM	IMUNON Releases Enterprise Video Highlighting the Companys Mission, Vision, Values, Breakthroughs and Technologies (GlobeNewswire)
Sep-18-23 07:08AM	IMNN: R&D Day Highlights Company Pipeline (Zacks)
Sep-13-23 08:30AM	IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET (GlobeNewswire)
Sep-07-23 04:30PM	IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET (GlobeNewswire) -5.74%
Sep-05-23 08:30AM	IMUNON to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 12:09PM	Imunon Inc's Rocky Road Ahead: Unraveling the Factors Limiting Growth (GuruFocus.com) +9.01%
11:38AM	Is Imunon (IMNN) Modestly Overvalued? A Comprehensive Valuation Analysis (GuruFocus.com)
Aug-24-23 04:05PM	IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus (GlobeNewswire)
Aug-22-23 09:25AM	IMNN: Manuscript Preprint on COVID-19 DNA Vaccine Published (Zacks Small Cap Research)
Aug-15-23 06:11AM	Imunon, Inc. (NASDAQ:IMNN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-14-23 08:30AM	IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla (GlobeNewswire)
Aug-11-23 04:16AM	Q2 2023 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 08:00AM	IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 08:30AM	Preclinical Data Showing Strong Immunogenicity and Protection with IMUNONs PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv (GlobeNewswire)
Aug-03-23 08:30AM	IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023 (GlobeNewswire)
Jul-12-23 05:00AM	KFC China Celebrates its 500th Store in Shanghai (PR Newswire)
Jun-27-23 12:00PM	IMUNON Unveils New Manufacturing Capabilities at Huntsvilles HudsonAlpha Biotech Campus (GlobeNewswire)
Jun-26-23 05:00PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Jun-12-23 08:30AM	IMUNON CEO to Discuss Companys Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023 (GlobeNewswire) +5.71%
Jun-08-23 08:30AM	IMUNONs CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention (GlobeNewswire)
May-30-23 08:00AM	IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells Gordon Research Conference (GlobeNewswire)
May-17-23 09:07AM	IMNN: Preclinical Data Suggests Testing BiWeekly Dosing of IMNN-001 (Zacks Small Cap Research)
May-12-23 02:03AM	Q1 2023 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 08:00AM	IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.19%
May-04-23 08:30AM	IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023 (GlobeNewswire)
Apr-19-23 08:30AM	IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001 (GlobeNewswire) +16.03%
Apr-13-23 08:13AM	IMNN: PLACCINE Technology Presented at Vaccine Technology Summit (Zacks Small Cap Research)
Apr-01-23 08:41AM	Imunon Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Mar-30-23 08:00AM	IMUNON Reports 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-23 08:30AM	IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023 (GlobeNewswire)
Mar-22-23 08:00AM	IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023 (GlobeNewswire)
Mar-21-23 04:30PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Mar-15-23 02:00PM	IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-01-23 08:45AM	IMUNON CEO Issues Letter to Shareholders (GlobeNewswire)
Feb-27-23 08:30AM	IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer (GlobeNewswire)
Jan-12-23 08:30AM	IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses (GlobeNewswire)
Jan-05-23 08:30AM	IMUNON Enters into Collaborative Research Agreement with The Wistar Institutes Vaccine & Immunotherapy Center to Research IMUNONs PLACCINE Vaccine Platform (GlobeNewswire)
Dec-14-22 08:30AM	IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Dec-01-22 04:00PM	IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages (GlobeNewswire) +5.00%
Nov-30-22 09:27AM	IMNN: Promising Preclinical Results for PLACCINE Platform (Zacks Small Cap Research)
Nov-22-22 08:30AM	IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 December 1, 2022 (GlobeNewswire)
Nov-17-22 08:30AM	IMUNON Announces Strategic Investment in Transomic Technologies (GlobeNewswire)
Nov-14-22 08:00AM	IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-22 08:30AM	IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNONs PLACCINE Plasmid DNA with Acuitas Lipid Nanoparticle Delivery System (GlobeNewswire)
Nov-07-22 08:30AM	Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022 (GlobeNewswire)
Oct-03-22 05:00PM	Imunon Appoints James E. Dentzer to its Board of Directors (GlobeNewswire)
08:00AM	Imunon Reports Partial Results from Ongoing Non-human Primate Study (GlobeNewswire)
Sep-29-22 05:00PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Sep-27-22 08:30AM	IMUNON to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lindborg Stacy	President and CEO	Aug 15 '24	Buy	0.98	25,000	24,500	264,166	Aug 16 08:03 AM
Tardugno Michael H	Executive Chairman of Board	Aug 15 '24	Buy	1.03	25,000	25,750	353,346	Aug 16 08:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNN

Imunon Inc

Upgrade your FINVIZ experience